Veracyte(US:VCYT)2026-01-12 11:05Revenue Projections - Veracyte expects total revenue for Q4 2025 to be between $138 million and $140 million, with testing revenue between $134 million and $136 million[5]. - For the full year 2025, Veracyte expects total revenue between $515 million and $517 million, with testing revenue between $491 million and $493 million[5]. Testing Volume - The company anticipates testing volume of approximately 45,500 tests for Q4 2025[5]. - The projected testing volume for the full year 2025 is approximately 169,700 tests[5]. Financial Metrics - Veracyte expects an adjusted EBITDA margin of greater than 25% for the full year 2025[5]. - The company is unable to provide an estimate of net income margin for the full year 2025 due to the unavailability of reliable estimates[6]. - Key components affecting net income margin may include stock-based compensation expenses and acquisition-related expenses[6]. Financial Reporting - The preliminary financial results are subject to completion of financial closing procedures and audit adjustments[6]. - Veracyte's audited financial statements for the full year ended December 31, 2025, are not yet available[6]. - The press release regarding these results was issued on January 11, 2026[5].